US FDA inspection completed at Caplin Steriles Injectable site at Gummidipoondi

Caplin Point Laboratories Limited has announced that the United States Food and Drug Administration (USFDA) had completed its GMP and PAI inspection of Caplin Steriles Limited's (a subsidiary of Caplin Point Laboratories Limited) Sterile Injectable site at Gummidipoondi between May 22nd to 31st.

At the end of the inspection, there were four observations by US FDA. These observations are procedural in nature and the corrective and preventive actions for these observations will be presented to the US FDA within the stipulated period. The observations made were not repeat observations or related to data integrity.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 743.40 as compared to the previous close of Rs. 735.85. The total number of shares traded during the day was 3821 in over 465 trades.

The stock hit an intraday high of Rs. 751.00 and intraday low of 732.20. The net turnover during the day was Rs. 2847730.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 CaplinSteriles USFDA GMP PAI Inspection 4Observations